The University of Tokyo,  The Institute of Medical Science, Division for AIDS Vaccine Development
National Institute of Infectious Diseases, AIDS Research Center, Groups 1 and 2

updated on April 7, 2021

• The research article by Dr. Midori Nakamura-Hoshi was published in Sci Rep. (2020.7.9)

Nakamura-Hoshi, M., Takahara, Y., Matsuoka, S., Ishii, H., Seki, S., Nomura, T., Yamamoto, H., Sakawaki, H., Miura, T., Tokusumi, T., Shu, T., and Matano, T.* Therapeutic vaccine-mediated Gag-specific CD8+ T-cell induction under anti-retroviral therapy augments anti-virus efficacy of CD8+ cells in simian immunodeficiency virus-infected macaques. Sci. Rep. 10:11394, 2020.

• The research article by Dr. Hiroshi Ishii was published in J Virol. (2020.3.31)

Ishii, H., Terahara, K., Nomura, T., Takeda, A., Okazaki, M., Yamamoto, H., Tokusumi, T., Shu, T., and Matano, T.* A novel immunogen selectively eliciting CD8+ T cells but not CD4+ T cells targeting immunodeficiency virus antigens. J. Virol. 94:e01876-19, 2020.

• The research article by Dr. Saori Matsuoka was published in Prev Med Rep. (2019.10.21)

Matsuoka, S., Nagashima, M., Sadamasu, K., Mori, H., Kawahata, T., Zaitsu, S., Nakamura, A., de Souza, M.S., and Matano, T.* Estimating HIV-1 incidence in Japan from the proportion of recent infections. Prev. Med. Rep. 16:100994, 2019.

• The result of a phase I clinical trial using SeV vector (S001) was reported in J. Infect. Dis. (2016.10.17)

Nyombayire, J., Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C.L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J.-L., Fast, P., Laufer, D.S., Cox, J.H., and the S001 Study Team. First-in-human evaluation of the safety and immunogenicity of a replicating intranasally administered Sendai HIV-1 Gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis., 215:95-104. 2017.

• GHIT has announced to the award for a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID. (2016.10.5)

This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection. 

    GHIT press room     GHIT web site     VLP Therapeutics web site

• The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations, England, Kenya and Rwanda. The SeV vector AIDS vaccine system has been developed by our research group. (2013.4.2)


     Information on this project in IAVI Web

>> AIDS Research Center website


Matano Research Group

Welcome to Our Lab!

Contact us

AIDS Research Center
National Institute of Infectious Diseases

1-23-1 Toyama, Shinjuku-ku

Tokyo 162-8640, Japan

Department of AIDS Vaccine Development
The Institute of Medical Science

The University of Tokyo

TEL: 03-5285-1111 (ext. 2302) 

FAX: 03-5285-1165